XML 33 R45.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity (Details Textual) (USD $)
 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended
Dec. 23, 2003
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2013
Common Stock [Member]
Dec. 31, 2013
Accredited Investors [Member]
Dec. 31, 2013
Underwritten Offering [Member]
Dec. 31, 2013
Performance Shares [Member]
Jun. 28, 2013
Restricted Stock [Member]
Dec. 31, 2013
Restricted Stock [Member]
Dec. 31, 2010
Restricted Stock [Member]
Dec. 31, 2013
Restricted Stock Award [Member]
Dec. 31, 2013
2011 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized                       1,783,292
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant                       304,673
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights                 Ten percent of the issued restricted common stock vested on December 31, 2011. The remaining ninety percent of the restricted shares were modified on January 31, 2013 to vest on the earlier of the first dosing in the pivotal clinical study for its lead drug candidate, or 50% on January 31, 2014 and 50% on January 31, 2015.      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value                   $ 5.75 $ 0  
Treasury Stock, Shares, Acquired               8,626        
Treasury Stock Acquired, Average Cost Per Share               $ 6.16        
Share-based Compensation, Total   $ 979,151 $ 127,488         $ 16,000        
Class Of Warrant Or Right Issued 20,467                      
Class Of Warrant Or Right Exercise Price Of Warrants Issued $ 12.21                      
Class Of Warrant Or Right Amended Expiration Date Dec. 31, 2015                      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period                 12,000 112,720    
Stock Issued During Period, Shares, New Issues       1,715,800 6,336,664 1,715,800     15,000      
Proceeds from Issuance of Common Stock   12,809,126 0   35,700,000 12,500,000            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares             907,336          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Exercise Price, Beginning Balance             $ 2.81          
Allocated Share-based Compensation Expense   979,151 127,488       422,000          
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award   the Company modified the vesting terms for its unvested performance based stock options and unvested restricted common stock of fifteen employees and non-employee directorsto vest on the earlier of the first closing in the pivotal clinical study for its lead drug candidate, or 50% on January 31, 2014 and 50% on January 31, 2015.         the Company modified 907,336 existing time-vested and performance stock options by lowering the exercise price to $2.81. Additionally, the Company modified the vesting terms for its unvested performance stock options and unvested restricted stock to vest on the earlier of the first dosing in the pivotal clinical study for its lead drug candidate, or 50% on January 31, 2014 and 50% on January 31, 2015          
Payments of Stock Issuance Costs         2,300,000 1,600,000            
Stock Issued During Period, Value, Issued in Settlement for Termination of Certain Rights in Stock Purchase Agreement   913,446   15                
Stock Issued During Period, Shares, Issued in Settlement for Termination of Certain Rights in Stock Purchase Agreement       152,241                
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value   $ 12,000 $ 0